Baseline comparison of NASH vs non-NASH liver transplant recipients
| NASH (n=10) | Non-NASH (n=36) | P value | |
| Age, years | 56.5 (15.2) | 56.8 (8.3) | 0.939 |
| Male sex | 70 (7) | 83 (30) | 0.974 |
| BMI, mean kg/m2 | 33.8 (7.9) | 29.8 (5.6) | 0.16 |
| Laboratories | |||
| Creatinine (mg/dL) | 1.8 (0.9) | 1.1 (0.5) | 0.003 |
| INR | 3.3 (1.1) | 2.2 (1.3 | 0.014 |
| MELD score | 37.0 (3.0) | 33.0 (7.0) | 0.088 |
| Sodium (mEq/L) | 132.9 (12.0) | 138.0 (5.9) | 0.069 |
| Total bilirubin (mg/dL) | 18.2 (13.5) | 9.3 (9.4) | 0.022 |
| Portal hypertension | |||
| Ascites | 60 (6) | 42 (15) | 0.69 |
| Gastro-oesophageal varices | 60 (6) | 44 (16) | 0.736 |
| Hepatic encephalopathy | 70 (7) | 42 (15) | 0.651 |
| Metabolic risk factors | |||
| Diabetes | 5 (50) | 5 (14) | 0.001 |
| Hyperlipidaemia | 3 (30) | 1 (3) | <0.001 |
| Hypertension | 5 (50) | 9 (25) | 0.2 |
| PAI-1 (mg/mL) | 53.9 (26.8) | 36.1 (21.3) | 0.04 |
Categorical variables are presented as % (n); continuous variables are presented as mean (standard deviation).
In general, NASH and non-NASH recipients except for a greater frequency of metabolic risk factors in the NASH group and greater PAI-1 levels.
BMI, body mass index; INR, international normalised ratio; MELD, Model for End Stage Liver Disease; NASH, non-alcoholic steatohepatitis; PAI, plasminogen activator inhibitor.